Understanding how BRCA2 mutations affect prostate cancer treatment responses

Who could benefit from this research

What this research studies

This research investigates the biological mechanisms behind therapy resistance in prostate cancers with BRCA2 mutations, particularly focusing on the effectiveness of PARP inhibitors. By utilizing new patient-derived models, the study aims to uncover how these cancers adapt to treatment and develop resistance. Patients with advanced castrate-resistant prostate cancer (CRPC) will be studied to identify potential strategies to enhance treatment responses and overcome resistance. The research employs advanced sequencing techniques and analysis of gene expression to understand the underlying biological changes.

Why it matters

Where this research is happening

• Ut Southwestern Medical Center
  Dallas, United States Active

Researchers

• Principal investigator: Hofstad, Mia E — Ut Southwestern Medical Center
• Study coordinator: Hofstad, Mia E

Related research

Other NIH-funded projects on the same topics.

• Ariginine-depleting therapy plus chemotherapy for aggressive variant prostate cancers

  This project tests whether removing arginine from the body enhances chemotherapy for men with a difficult-to-treat prostate cancer subtype.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11391400

• Targeting master regulators to overcome AR-driven resistance in advanced prostate cancer

  This grant explores how cancer cells rewire their growth signals to resist AR-targeted therapies in advanced prostate cancer and tests new ways to block those master regulators.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11369845

• Lowering arginine with chemotherapy for aggressive prostate cancer

  Looks at whether lowering a nutrient called arginine together with platinum‑taxane chemotherapy can help men with aggressive, treatment‑resistant prostate cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11174404

• Targeting key regulators in advanced prostate cancer that resist standard treatments

  This research looks for new ways to treat advanced prostate cancer that has stopped responding to common hormone therapies.

  NIH research State University of New York at Buffalo · Amherst, United States · NIH-11159586

• Investigating the impact of arginine depletion with chemotherapy in aggressive prostate cancers

  This study is looking at how lowering levels of an amino acid called arginine might make chemotherapy work better for men with aggressive prostate cancer that doesn't respond well to regular treatments.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-10932183

• Targeting DNA repair pathways in prostate cancer

  This study is looking at whether a special combination of treatments can help men with non-castrate prostate cancer, especially those with certain genetic changes, by focusing on fixing DNA damage to improve their chances of recovery.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10922777

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.